- Email: [email protected]
8505030 Drug preparations of reduced toxicity
350
PATENT ABSTRACTS
such polypeptides, and antibodies which are capable of recognizing and specifically binding to them.
8504871 LEUKEMIA-ASSOCIATED VIRUS IMMUNOGEN, VACCINE AND ASSAY John H ELDER, Richard A HOUGHTEN assigned to SCRIPPS CLINIC AND RESEARCH FOUNDATION A leukemia-associated virus immunogens, vaccines, antibody combining sites and assays. The immunogens are relatively short polypeptides with peptide sequences corresponding to the antigenic determinant domains of a leukemiaassociated virus envelope protein. The immunogens when introduced into a host stimulate the production of antibodies which immunoreact with the polypeptides and the leukemiaassociated virus.
8504984 CMOS INTEGRATED CIRCUIT TECHNOLOGY Steven James HILLENIUS, Louis Carl PARRILLO assigned to AMERICAN TELEPHONE & TELEGRAPH COMPANY
To minimize the number of independent masking operations in the manufacture of a CMOS integrated circuit device using twin tub technology, the n-tub is made by separate phosphorus and arsenic implants through a mask (13-16) and the p-tub is made by two separate boron implants through a mask (13A, B) derived from that used for forming the n-tub. One of the boron implants occurs before, the other after, a drive-in heating step. After tub formation, further movement of the implanted ions is kept small by use of a high pressure process for growing the field oxide and by only limited further heating. Transistors are then formed in the tubs.
8505029
8504880
ORAL INSULIN AND A METHOD OF MAKING THE SAME
FUSED LIPOSOME AND ACID INDUCED METHOD FOR LIPOSOME FUSION
Bernard ECANOW, Charles S ECANOW, Charles S ECANOW assigned to MEDAPHORE INC;
Leaf HUANG, Jerome CONNOR assigned to UNIVERSITY OF TENNESSEE RESEARCH CORPORATION
A composition of matter useful as an oral dosage form of insulin based upon a two phase liquid aqueous system in which insulin component or components are incorporated. The invention also provides for a method of preparing the oral dosage form of insulin, as well as a further process whereby sustained release dosage forms of oral insulin are produced. The oral form of insulin eliminates or reduces the need to use injection as a mode of administering insulin.
Liposomes containing phosphatidylethanolamine, palmitoyl homocysteine or oleic acid or palmitic acid, fuse rapidly when the pH of the medium is reduced below 7. Liposome fusion was measured by (a) mixing of the iiposomal lipids as shown by resonance energy transfer, (b) gel filtration and (c) electron microscopy. The presence of phosphatidylethanolamine or acid addition esters thereof in the liposomes greatly enhances fusion; whereas the presence of phosphatidylcholine inhibits fusion. During fusion of liposomes containing phosphatidylethanolamine: palmitoyl homocysteine (8:2), almost all of the encapsulated calcein is released. Inclusion ofcholesterol (40~o) in the liposomes substantially decreases leakage without impairing fusion. Those pH sensitive liposomes are fused to deliver biologically active molecules such as DNA, into living cells.
8505030 DRUG PREPARATIONS OF REDUCED TOXICITY Andrew Stuart JANOFF. Mircea Constantine POPESCU, Carl R ALVING, Carl R ALVING assigned to THE L1POSOME COMPANY 1NC; Preparations of drugs in admixture with certain ligands which, when administered to animals or
351
PATENT ABSTRACTS
humans, are less toxic than conventional drug preparations. Although the toxicity of the drugligand preparations described is greatly reduced, the drug retains pharmacological activity.
8505031 A M E T H O D FOR THE M O D U L A T I O N OF THE I M M U N E RESPONSE Barry William N I N H A M , Robert Vincent BLANDEN, Robert Brian A S H M A N , 18 Booth Crescent, Cook, ACT 2614, Australia assigned to THE A U S T R A L I A N NATIONAL UNIVERSITY A method of modulating or suppressing the immune response of an animal comprises the administration of an effective amount of at least one amphiphile which is capable o f interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell. A method of preparing animal tissue for grafting or transplantation from a donor animal to a recipient animal, and immunosuppressant compositions, are also disclosed. Preferably, the amphiphile is a cationic surfactant, such as a double-chained quarternary ammonium surfactant.
8505034 C O M P O S I T I O N S FOR THE ALLEVATION, TREATMENT AND DIAGNOSIS OF ARTHRITIC DISEASE AND RELATED CONDITIONS John Lawson STANFORD,. lrun Robert COHEN, Ayala FRENKEL, Joseph HOLOSHITZ, EDEN Willem VAN, Graham Arthur William ROOK, Mill House, Claygate, Marden, Kent, United Kingdom assigned to UNIVERSITY COLLEGE LONDON; YEDA RESEARCH A N D D E V E L O P M E N T CO LTD; The invention provides pharmaceutical compositions for the alleviation of arthritic diseases. These contain as active ingredient mycobacteria or fractions of these, e.g. obtained by fractionation in certain solvents. The compositions can also be used for vaccinations. There is also provided an assay for the diagnosis of arthritic diseases, and a kit for carrying such an assay.
8505035 A SUBSTITUTE FOR H U M A N BLOOD AND A M E T H O D OF MAKING THE SAME Bernard ECANOW, Charles S ECANOW, Charles S ECANOW assigned to N E O M E D INC; The method of this invention yields a two phase liquid aquous system which replicates the two phase heterogeneous physico-chemical system of naturally securing whole human blood. The method produces: (1) a composition o f matter which comprises an oxygen transport solution: (2) when pyridoxalated-polymerized hemoglobin and other specific additives are incorporated, said composition comprises a synthetic blood useful as a physiological substitute for human blood; and (3) when said blood substitute is processed further, yields a microencapsulated composition with time released characteristics that can transport oxygen. The invention overcomes the obstacles that have prevented the use of pyridoxalated-polymerized hemoglobin and other forms of modified hemoglobin in the preparation of oxygen transport solutions.
8505036 TOPICAL TREATMENT OF DIABETES WITH INSULIN AND PENETRANT ENHANCER APPLIED TO THE SKIN AND COVERED BY A PATCH Collin J WEBER, Michael KAZIM, Keith REEMTSMA, John F NICHOLSON assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF A composition, which when applied to the surface o f the skin of a diabetic subject is useful for treating diabetes, includes a first layer in contact with the skin surface and a second layer covering the first layer. The first layer contains an effective amount of insulin for treating diabetes, an effective enhancing amount of a penetrant enhancer and a suitable carrier. The second layer comprises a suitable adherent, nonporous patch material. In a preferred embodiment, the first layer is in the form of a gel and includes a suitable gel material. Application of the composition to the surface of a diabetic subject's skin for a sufficient period of time to permit insulin present in the composition to cross the skin provides a method for treating diabetes.
PATENT ABSTRACTS
such polypeptides, and antibodies which are capable of recognizing and specifically binding to them.
8504871 LEUKEMIA-ASSOCIATED VIRUS IMMUNOGEN, VACCINE AND ASSAY John H ELDER, Richard A HOUGHTEN assigned to SCRIPPS CLINIC AND RESEARCH FOUNDATION A leukemia-associated virus immunogens, vaccines, antibody combining sites and assays. The immunogens are relatively short polypeptides with peptide sequences corresponding to the antigenic determinant domains of a leukemiaassociated virus envelope protein. The immunogens when introduced into a host stimulate the production of antibodies which immunoreact with the polypeptides and the leukemiaassociated virus.
8504984 CMOS INTEGRATED CIRCUIT TECHNOLOGY Steven James HILLENIUS, Louis Carl PARRILLO assigned to AMERICAN TELEPHONE & TELEGRAPH COMPANY
To minimize the number of independent masking operations in the manufacture of a CMOS integrated circuit device using twin tub technology, the n-tub is made by separate phosphorus and arsenic implants through a mask (13-16) and the p-tub is made by two separate boron implants through a mask (13A, B) derived from that used for forming the n-tub. One of the boron implants occurs before, the other after, a drive-in heating step. After tub formation, further movement of the implanted ions is kept small by use of a high pressure process for growing the field oxide and by only limited further heating. Transistors are then formed in the tubs.
8505029
8504880
ORAL INSULIN AND A METHOD OF MAKING THE SAME
FUSED LIPOSOME AND ACID INDUCED METHOD FOR LIPOSOME FUSION
Bernard ECANOW, Charles S ECANOW, Charles S ECANOW assigned to MEDAPHORE INC;
Leaf HUANG, Jerome CONNOR assigned to UNIVERSITY OF TENNESSEE RESEARCH CORPORATION
A composition of matter useful as an oral dosage form of insulin based upon a two phase liquid aqueous system in which insulin component or components are incorporated. The invention also provides for a method of preparing the oral dosage form of insulin, as well as a further process whereby sustained release dosage forms of oral insulin are produced. The oral form of insulin eliminates or reduces the need to use injection as a mode of administering insulin.
Liposomes containing phosphatidylethanolamine, palmitoyl homocysteine or oleic acid or palmitic acid, fuse rapidly when the pH of the medium is reduced below 7. Liposome fusion was measured by (a) mixing of the iiposomal lipids as shown by resonance energy transfer, (b) gel filtration and (c) electron microscopy. The presence of phosphatidylethanolamine or acid addition esters thereof in the liposomes greatly enhances fusion; whereas the presence of phosphatidylcholine inhibits fusion. During fusion of liposomes containing phosphatidylethanolamine: palmitoyl homocysteine (8:2), almost all of the encapsulated calcein is released. Inclusion ofcholesterol (40~o) in the liposomes substantially decreases leakage without impairing fusion. Those pH sensitive liposomes are fused to deliver biologically active molecules such as DNA, into living cells.
8505030 DRUG PREPARATIONS OF REDUCED TOXICITY Andrew Stuart JANOFF. Mircea Constantine POPESCU, Carl R ALVING, Carl R ALVING assigned to THE L1POSOME COMPANY 1NC; Preparations of drugs in admixture with certain ligands which, when administered to animals or
351
PATENT ABSTRACTS
humans, are less toxic than conventional drug preparations. Although the toxicity of the drugligand preparations described is greatly reduced, the drug retains pharmacological activity.
8505031 A M E T H O D FOR THE M O D U L A T I O N OF THE I M M U N E RESPONSE Barry William N I N H A M , Robert Vincent BLANDEN, Robert Brian A S H M A N , 18 Booth Crescent, Cook, ACT 2614, Australia assigned to THE A U S T R A L I A N NATIONAL UNIVERSITY A method of modulating or suppressing the immune response of an animal comprises the administration of an effective amount of at least one amphiphile which is capable o f interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell. A method of preparing animal tissue for grafting or transplantation from a donor animal to a recipient animal, and immunosuppressant compositions, are also disclosed. Preferably, the amphiphile is a cationic surfactant, such as a double-chained quarternary ammonium surfactant.
8505034 C O M P O S I T I O N S FOR THE ALLEVATION, TREATMENT AND DIAGNOSIS OF ARTHRITIC DISEASE AND RELATED CONDITIONS John Lawson STANFORD,. lrun Robert COHEN, Ayala FRENKEL, Joseph HOLOSHITZ, EDEN Willem VAN, Graham Arthur William ROOK, Mill House, Claygate, Marden, Kent, United Kingdom assigned to UNIVERSITY COLLEGE LONDON; YEDA RESEARCH A N D D E V E L O P M E N T CO LTD; The invention provides pharmaceutical compositions for the alleviation of arthritic diseases. These contain as active ingredient mycobacteria or fractions of these, e.g. obtained by fractionation in certain solvents. The compositions can also be used for vaccinations. There is also provided an assay for the diagnosis of arthritic diseases, and a kit for carrying such an assay.
8505035 A SUBSTITUTE FOR H U M A N BLOOD AND A M E T H O D OF MAKING THE SAME Bernard ECANOW, Charles S ECANOW, Charles S ECANOW assigned to N E O M E D INC; The method of this invention yields a two phase liquid aquous system which replicates the two phase heterogeneous physico-chemical system of naturally securing whole human blood. The method produces: (1) a composition o f matter which comprises an oxygen transport solution: (2) when pyridoxalated-polymerized hemoglobin and other specific additives are incorporated, said composition comprises a synthetic blood useful as a physiological substitute for human blood; and (3) when said blood substitute is processed further, yields a microencapsulated composition with time released characteristics that can transport oxygen. The invention overcomes the obstacles that have prevented the use of pyridoxalated-polymerized hemoglobin and other forms of modified hemoglobin in the preparation of oxygen transport solutions.
8505036 TOPICAL TREATMENT OF DIABETES WITH INSULIN AND PENETRANT ENHANCER APPLIED TO THE SKIN AND COVERED BY A PATCH Collin J WEBER, Michael KAZIM, Keith REEMTSMA, John F NICHOLSON assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF A composition, which when applied to the surface o f the skin of a diabetic subject is useful for treating diabetes, includes a first layer in contact with the skin surface and a second layer covering the first layer. The first layer contains an effective amount of insulin for treating diabetes, an effective enhancing amount of a penetrant enhancer and a suitable carrier. The second layer comprises a suitable adherent, nonporous patch material. In a preferred embodiment, the first layer is in the form of a gel and includes a suitable gel material. Application of the composition to the surface of a diabetic subject's skin for a sufficient period of time to permit insulin present in the composition to cross the skin provides a method for treating diabetes.